Insider buying last 90 days
No open-market insider purchases were filed for MLYS in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every MLYS insider filing, plotted on the chart in Gekko.Open MLYS in Gekko
NASDAQ: MLYS
Mineralys Therapeutics (MLYS) Stock Analysis & Forecast
Oct 12 close
$22.23−1.14 (−4.9%)
Gekko Brief
AI summaryOct 12 closeMineralys Therapeutics draws mixed analyst reaction this week around lorundrostat, its blood pressure drug under FDA review ahead of a December 22 PDUFA date. HC Wainwright & Co. reiterated a Buy rating with a $56 price target, citing new data presented at the AHA Hypertension Scientific Sessions 2026 showing efficacy in difficult-to-treat hypertension and obstructive sleep apnea. UBS struck a different note, initiating coverage with a Neutral rating and a $29.00 price target. The stock also touched a 52-week low of $22.23 this week, which the company attributes partly to a wider-than-expected Q2 2026 loss tied to spending on the drug's development.
The stock closed at $22.23, down 4.9%, and sits below both its 50-day average of $26.39 and 200-day average of $27.99, with the shorter average also below the longer one. The GekkoIndex reads 67.3, placing MLYS in the Accumulation zone. Price remains 30.3% below the Gekko Fair Value of $31.88.
Looking ahead, MLYS reports earnings on 9 November 2026, 27 days out, falling inside a typical 20-trading-day holding window; its last report showed a wider actual loss of $2.85 per share against a $0.57 estimate, with a -1.2% reaction. No insider, Congress, or unusual options activity appears in the current window. Seasonality over the next 20 trading days has averaged -3.5% across 3 years, with gains in only 1 of them. Consensus among 7 firms stands at 6 buy and 1 hold, with a consensus target of $48.50.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Mineralys Therapeutics price vs fair value
Close $22.23200-day averageGekko Fair Value $31.88
Mineralys Therapeutics quick facts
- Market cap
- $1.96B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$4.22
- Revenue, TTM
- $0
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 0.69
- Volume
- 1.00M avg 1.43M
- 1-year return
- −43.6%
- Typical daily move
- ±6.2%
- Typical 20-day move
- ±11.6%
- 50-day average
- $26.39
- 200-day average
- $27.99
- Next earnings
- Nov 9
- Shares outstanding
- 88.41M
Mineralys Therapeutics swing-trade checklist
Mineralys Therapeutics scores 2 supportive, 0 mixed and 3 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive0 mixed3 headwinds
- Trendheadwind
Below 50 and 200-day
Close $22.23 is below the 50-day ($26.39) and 200-day ($27.99) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexsupportive
67.3, Accumulation
Reading 67.3 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
30.3% below
Price is 30.3% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 28 days
Reports on Nov 9, 2026, 28 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−3.5% on average
From this point in the calendar, the next 20 trading days averaged −3.5% over 3 years, rising in 1 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Mineralys Therapeutics stock chart and price history
Mineralys Therapeutics closed at $22.23 on Oct 12, 2026, −43.6% over the past year, inside a 52-week range of $21.46 to $47.65.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −21.2%
- 3 months
- −18.5%
- 6 months
- −18.2%
- 1 year
- −43.6%
The full MLYS chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open MLYS in Gekko
Follow Mineralys Therapeutics through every session
Put MLYS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track MLYS in GekkoFree for 7 days. No credit card required.
About Mineralys Therapeutics
Mineralys Therapeutics works in clinical-stage biopharmaceutical research, aiming its efforts at conditions linked to excess aldosterone in the body. Its main candidate, lorundrostat, is an orally taken compound designed to selectively block aldosterone synthase, and it is best known for pursuing this treatment path toward cardiorenal problems tied to aldosterone overproduction.
The company's work centers on advancing lorundrostat through development for conditions such as hypertension and chronic kidney disease, both of which can be driven by abnormally high aldosterone levels. As a clinical-stage firm, its efforts are concentrated on this single proprietary compound rather than a marketed product line.
Mineralys Therapeutics was established by Brian Taylor Slingsby on May 31, 2019, and its headquarters are located in Radnor, Pennsylvania. Its shares are listed on the NASDAQ under the ticker MLYS.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- mineralystx.com
Mineralys Therapeutics GekkoIndex: the smart money zone
Mineralys Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 67.3, in the Accumulation zone, down 1.4 points over five sessions.
67.3Accumulation
Down 1.4 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 31 | +5.0% | +13.3% | ||
| Accumulation (current zone) | 256 | +1.6% | +8.1% | ||
| Neutral | 333 | +0.2% | +3.3% | ||
| Distribution | 54 | +4.2% | +1.8% | ||
| Selling | 8 | Too few readings yet | |||
Average MLYS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the MLYS price, zone by zone.Track MLYS in Gekko
Is Mineralys Therapeutics stock overvalued? Gekko Fair Value
Mineralys Therapeutics trades 30.3% below Gekko Fair Value of $31.88, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Mineralys Therapeutics shares are worth, recalculated every trading day.
$31.88
Gekko Fair Value, Oct 10, 2026
30.3% Undervalued
At the end of Aug 2026 the price was 37.3% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open MLYS in Gekko
Mineralys Therapeutics insider and Congress trading
No open-market insider purchases were filed for Mineralys Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in MLYS were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for MLYS, plotted on the chart in Gekko.Open MLYS in Gekko
Buybacks
Mineralys Therapeutics has been buying back its own shares.
- Bought back, year ended Dec 31, 2022
- $1.63M
- As a share of market cap
- 0.08%
From company filings.
Mineralys Therapeutics earnings: next date and track record
Mineralys Therapeutics reports on Nov 9, 2026 (28 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Nov 9, 2026
28 days away
- EPS estimate
- −$0.53
5 of 8reports beat the EPS estimate
±6.1%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 11, 2026 AI summary
- What they said
- Mineralys Therapeutics (MLYS) provided Q2 2026 updates focused on commercial launch readiness ahead of a December 22 PDUFA date for lorundrostat. Clinical data showed meaningful blood pressure reductions in CKD patients and a 52% placebo-adjusted reduction in urine albumin-to-creatinine ratio. Proteomic data showed lorundrostat reduced biomarkers of heart failure risk. The company repurchased Mitsubishi Tanabe royalty rights for $200M upfront plus up to $100M in milestone payments.
- Guidance
- Management is building commercial infrastructure ahead of the December 22, 2026 PDUFA date for lorundrostat. The company is evaluating partnering opportunities and further clinical development plans, with updates to be communicated as appropriate.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 11, 2026 | −$2.85 est −$0.57 | — | −1.2% |
| May 6, 2026 | −$0.47 est −$0.44 | — | +0.2% |
| Mar 12, 2026 | −$0.40 est −$0.94 | — | −6.4% |
| Nov 10, 2025 | −$0.52 est −$0.61 | — | +23.9% |
| Aug 12, 2025 | −$0.66 est −$0.78 | — | +2.8% |
| May 12, 2025 | −$0.79 est −$1.02 | — | +3.7% |
| Feb 12, 2025 | −$0.98 est −$1.08 | — | +5.6% |
| Nov 11, 2024 | −$1.13 est −$0.83 | — | −4.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Mineralys Therapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for Mineralys Therapeutics is $48.50, +118.2% from the last close, from 7 firms rating the stock in the last 90 days.
$48.50consensus 12-month target, +118.2% from the last close
Now $22.23Avg $48.50
Low $29High $56
Each firm’s latest rating in the last 90 days: 7 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 12 | UBS | $29 | +30.5% |
| Oct 12 | H.C. Wainwright | $56 | +151.9% |
| Oct 12 | Bank of America Securities | $49 | +120.4% |
| Oct 11 | UBS | $29 | +30.5% |
| Oct 11 | UBS | $29 | +30.5% |
+8.1%average 20-day move after past Accumulation readings
−3.5%average move over the next 20 trading days in the last 3 years
±6.2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Mineralys Therapeutics seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Mineralys Therapeutics averaged −3.5% across the last 3 years, rising in 1 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.5% | 2 of 3 |
| Next 10 trading days | −5.0% | 0 of 3 |
| Next 15 trading days | −7.6% | 1 of 3 |
| Next 20 trading days | −3.5% | 1 of 3 |
| Next 30 trading days | −15.5% | 0 of 3 |
For scale, MLYS’s typical 20-trading-day move in either direction is about 11.6%.
Mineralys Therapeutics market cap and key statistics
Mineralys Therapeutics’s market cap is $1.96B and revenue of $0 over the last twelve months.
Valuation
- Market cap
- $1.96B
- EPS, TTM
- −$4.22
- Gekko Fair Value
- $31.88
Trading
- Volume
- 1.00M
- Avg volume, 20 days
- 1.43M
- 52-week high
- $47.65
- 52-week low
- $21.46
- Shares outstanding
- 88.41M
Financials
- Revenue, TTM
- $0
- Profit margin
- 0%
- Return on equity
- -80.9%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.69
- Typical daily move
- ±6.2%
- Typical 20-day move
- ±11.6%
Mineralys Therapeutics stock news this week
Coverage of Mineralys Therapeutics this week reads positive: 6 positive, 3 neutral and 2 negative headlines.
- HC Wainwright & Co. reiterates Buy rating on Mineralys Therapeutics, $56 price targetTradingView, Oct 12
- H.C. Wainwright Reiterates Buy Rating on Mineralys Therapeutics, Inc. (MLYS)StreetInsider, Oct 12
- UBS initiates Mineralys Therapeutics stock with neutral rating By Investing.comInvesting.com Canada, Oct 12
- Mineralys Therapeutics, Inc. (MLYS) options chainYahoo Finance Australia, Oct 11
- Mineralys Therapeutics, Inc. (MLYS) Presents at American Heart Association Hypertension Scientific Sessions 2026 - Slideshow (NASDAQ:MLYS) 2026-10-09Seeking Alpha, Oct 9
- Mineralys Therapeutics Presents New Data for LorundrostatGlobeNewswire, Oct 9
Mineralys Therapeutics peers
Mineralys Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
Mineralys Therapeutics stock FAQ
What is Mineralys Therapeutics’s market cap?
Mineralys Therapeutics’s market cap is $1.96B at the Oct 12, 2026 close of $22.23, with 88.41M shares outstanding.
What is the Mineralys Therapeutics stock forecast?
The consensus analyst 12-month price target for Mineralys Therapeutics is $48.50, +118.2% from the last close. Of the 7 firms that rated the stock in the last 90 days, 6 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Mineralys Therapeutics stock overvalued or undervalued?
On Gekko’s estimate Mineralys Therapeutics is undervalued: the Oct 12, 2026 close of $22.23 is 30.3% below Gekko Fair Value of $31.88. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Mineralys Therapeutics report earnings next?
Mineralys Therapeutics is expected to report on Nov 9, 2026 (28 days away). Analysts expect earnings of −$0.53 per share. Mineralys Therapeutics beat the earnings estimate in 5 of its last 8 reports, moving 6.1% on average across the report.
What is Mineralys Therapeutics’s 52-week high and low?
Mineralys Therapeutics’s 52-week high is $47.65 and its 52-week low is $21.46; it closed at $22.23 on Oct 12, 2026, −43.6% over the past year.
Is Mineralys Therapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (gekkoindex and fair value) and 3 as headwinds (trend, earnings risk and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Mineralys Therapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.